Buckley Capital’s Views on Liquidia Corp. (LQDA)

Posted on 5 mins ago

Buckley Capital Advisors, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -0.5% (net) in the quarter compared to -7.7% return for iShares Russell 2000 Value Index and -9.5% return for the iShares Russell 2000 Index. In the quarter, Donald Trump’s aggressive tariff plans increased economic uncertainty. Although tariffs directly impact less than 5% of the portfolio, the firm was prepared for this situation. However, the widespread selling of stocks affected it significantly. The firm focuses on the fundamentally strong companies regardless of the economic environment. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its first-quarter 2025 investor letter, Buckley Capital Advisors highlighted stocks such as Liquidia Corporation (NASDAQ:LQDA). Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company that engages in the development and commercialization of various products for unmet patient needs. The one-month return of Liquidia Corporation (NASDAQ:LQDA) was 25.46%, and its shares gained 24.56% of their value over the last 52 weeks. On May 7, 2025, Liquidia Corporation (NASDAQ:LQDA) stock closed at $15.53 per share with a market capitalization of $1.326 billion.

Buckley Capital Advisors stated the following regarding Liquidia Corporation (NASDAQ:LQDA) in its Q1 2025 investor letter:

“Liquidia Corporation (NASDAQ:LQDA): Pulmonary arterial hypertension (PAH) is a serious and potentially life-threatening lung disease whose root causes span a wide range, from hereditary factors to underlying cardiovascular health conditions to systemic diseases like HIV and connective tissue disorders. PAH impacts an estimated half a million individuals around the globe, with around 50,000 American patients currently under treatment.